Genflow Biosciences Plc (LON:GENF, OTCQB:GENFF, FRA:WQ5), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, has announced its final results for the year ended 31 December 2025. The Annual Report will be available to view on the Company’s website at www.genflowbio.com and the full, unedited text of its final results can be found below.
2025 Highlights
· Dog aging program reached major clinical milestone: Proof-of-concept study initiated in March 2025 and dosing phase completed in December with no adverse events observed; CDAs were signed with leading animal health companies to explore potential commercial partnerships, with additional confidential agreements signed in 2026.
· MASH (GF-1002) advanced toward clinical readiness: Program repositioned to target advanced fibrosis; successful GMP production test completed with higher-than-expected yield; pivotal studies initiated to support CTA filing; €4m non-dilutive Wallonia grant reaffirmed, with first tranche slated for May 2026.
· Strengthened global intellectual property position: SIRT6 patent family expanded through publications across Europe, China, and Japan, supporting long-term protection of the platform.
· Expanded platform and development capabilities: MSA signed with CER Groupe to support pre-IND development in a GxP-compliant environment; AI partnership with Heureka Labs established to enhance genomic analysis and therapeutic design.
· The Company will post the Annual Report to shareholders and provide notice for its Annual General Meeting in the coming weeks.
